Leukemia research

010 CD72 NANOBODY CAR-T CELLS HAVE POTENT ANTITUMOR EFFICACY IN B CELL MALIGNANCIES.

Leukemia research

W. Temple, M. Nix, G. Wicaksono, D. Wang, P. Phojanakong, V. Steri, B. Hann, M. Hermiston, A. Wiita

Study of the levels of expression of two oncogenes, c-myc and c-myb, in acute and chronic leukemias of both lymphoid and myeloid lineage.

Leukemia research

Ferrari S, Torelli U, Selleri L, Donelli A, Venturelli D, Narni F, Moretti L, Torelli G

Differential patterns of expression of cell cycle-related genes in blast cells of acute myeloid leukemia.

Leukemia research

Torelli U, Selleri L, Venturelli D, Donelli A, Emilia G, Ceccherelli G, Turchi L, Torelli G

O-14 A reversible two-step model ofMDS/preleukemia: Transgenic mice expressing inducible BCL2 and mutant NRAS.

Leukemia research

R.A. Padua, N. Omidvar, S. Kogan, T.-H. Phan, R. West, D. Felsher, I. Weissmann, S. Thomas, J. Whittaker, A. Janin, M. Pla, G. Muftis, J.M. Bishop, C. Chomienne

Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib.

Leukemia research

Paquette RL, Nicoll J, Chalukya M, Gondek L, Jasek M, Sawyers CL, Shah NP, Maciejewski J

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.

Leukemia research

Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP

049 A TARGETED GENE EXPRESSION CLASSIFIER IDENTIFIES PEDIATRIC T-ALL PATIENTS AT HIGH RISK FOR END INDUCTION MINIMAL RESIDUAL DISEASE POSITIVITY.

Leukemia research

L. Meyer, Ritu P. Roy, B. Huang, S. Kimura, Petri Polonen, C. Delgado-Martin, T. Vincent, T. Ryan, B. Wood, Y. Liu, J. Zhang, C. Mullighan, T. Horton, M. Loh, M. Devidas, E. Raetz, R. Hayashi, S. Winter, K. Dunsmore, S. Hunger, D. Teachey, M. Hermiston, Adam B. Olshen